BLCO Bausch + Lomb Corporation logo

BLCO Bausch + Lomb Corporation

Healthcare
$15.92-1.42%ClosedMarket Cap: $5.68B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.89

P/S

1.09

EV/EBITDA

7.52

DCF Value

$9.06

FCF Yield

0.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

55.9%

Operating Margin

5.9%

Net Margin

-4.2%

ROE

-3.4%

ROA

-1.6%

ROIC

2.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$1.24B$-71.0M$
Q4 null$1.41B$-58.0M$
FY null$5.10B$-360.0M$
Q3 null$1.28B$-28.0M$

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$18.88

Target (Median)

$19.50

Target Range

$16.00 - $21.00

1 Strong Buy3 Buy9 Hold0 Sell1 Strong Sell
Evercore ISI GroupIn Line
2026-04-30
HC Wainwright & Co.Buy
2026-02-23
BarclaysEqual Weight
2026-02-19
CitigroupBuy
2026-02-19
StifelHold
2026-02-19

Trading Activity

Insider Trades

View All
Munsch Frederickofficer: SVP, Controller and CAO
SellThu May 07
Hashad Yehiaofficer: EVP of R&D and CMO
SellThu May 07
Eldessouky Samofficer: EVP and CFO
SellThu May 07
Bonnefoy Lucofficer: President, Surgical
SellThu May 07
ROBERTSON RUSSEL Cdirector
SellFri May 01

Company Info

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Country

CA

Exchange

Beta

0.59

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

Peers